How to progress safe and effective cell therapies for clinical use!

Sistemic to present miRNA-led cell characterisation at Stem Cell Europe

18^th July 2011: Sistemic, UK:  Sistemic believe cell characterisation is an essential element in progressing safe and effective cell therapies for mainstream clinical use.  They offer unique miRNA analytical services that provide reliable and cost-effective, characterisation and QC tools that are applicable to all cell systems. Toward this end, Dr Vincent O’Brien (Chief Scientific Officer) and Dr Verna McErlane (Director of Commercial Operations, International) will present data supporting the utility of miRNA in the provision of superior cell characterisation and QC methods at the forthcoming Stem Cells Europe conference (20-21 July 2011, Edinburgh). 

Dr. Vincent O’Brien will present a poster entitled; ‘A novel microRNA-based stem cell characterisation and monitoring tool’,and Verna McErlane will join: Marilyn Robertson, SSCN; Aidan Courtney, Roslin Cells; Dr. David Hay, Fibromed; and, Michael Leek, Immunosolv, at the Scottish Stem Cell Network (SSCN) Panel showcase, “Progress to Therapy and Market” on Wednesday 20 July at 5pm.

 Sistemic Ltd are a global company offering unique miRNA-based products and services such as SistemQC^TM, designed for the sophisticated molecular characterisation of cells, which combines robust miRNA profiling, statistical analysis and contextual analysis. Further information on all Sistemic’s proprietary services, including; SistemRNA^TM, SistemQC^TM, SistemTOX^TM and SistemKB^TM, can be found at: www.sistemic.co.uk

Please Contact:

Dr Verna McErlane, Director of Commercial Operations,  +44 7855376358